menu ☰
menu ˟

[Comment] Spondyloarthropathy: interleukin 23 and disease modification

23 May 2015

Prevention of progressive loss of normal articular structure and preservation of functional capability are central goals of therapeutic discovery in rheumatology. Despite the remarkably effective inhibition of structural damage in rheumatoid arthritis that was achieved with biological agents targeting tumour necrosis factor, and the ability to reduce signs and symptoms of disease in spondyloarthropathy with the same treatments, prevention of disease progression and bone pathology in seronegative spondyloarthropathies has been immensely challenging.

Click here to view the full article which appeared in The Lancet